)
Biovica International (BIOVIC) investor relations material
Biovica International Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved 56% year-over-year net sales growth in Q1, primarily driven by strong Pharma Services momentum.
Implemented organizational restructuring and cost-saving measures, including leadership changes and a refocused US commercial strategy.
Strengthened leadership with a new CEO and CFO, and proposed a renewed Board with commercial and life sciences expertise.
Positioned for the next phase of growth with a fully guaranteed SEK 29.2 million rights issue.
Financial highlights
Net sales reached KSEK 4,043, up from KSEK 2,596, a 56% increase year-over-year (57% in local currency).
Operating loss (EBIT) was KSEK -20,334, compared to KSEK -19,334, including KSEK 2,200 in restructuring costs.
Cash flow from operating activities improved to KSEK -16,100 from KSEK -17,196.
Cash and cash equivalents at quarter-end were KSEK 51,588, up from KSEK 16,305.
Earnings per share after dilution was SEK -0.07, compared to SEK -0.18 year-over-year.
Outlook and guidance
Updated strategic and financial plan to be communicated in the coming months.
Confident in having sufficient financial resources for at least twelve months, subject to rights issue completion.
Focus remains on sustainable, profitable growth through scientific innovation and commercial execution.
- Strong sales growth and improved financials set the stage for US-focused expansion.BIOVIC
Q4 25/26 - Q3 net sales up 46% year-over-year, with strong U.S. momentum and improved cash position.BIOVIC
Q3 25/26 - Q2 sales up 16% YoY, SEK 122.3m raised, and cash flow positivity targeted for 2027.BIOVIC
Q2 25/26 - US IVD sales up 72% year-over-year, SEK 122M raised, and growth momentum continues.BIOVIC
Q1 25/26 - US sales up 120% in Q4, major partnerships, and SEK 80M rights issue to fund expansion.BIOVIC
Q4 24/25 - Major U.S. contracts and clinical data drive growth, but sales and funding risks persist.BIOVIC
Q2 24/25 - US sales up 48–50%, cash flow improved, but next year's funding depends on warrants.BIOVIC
Q1 24/25 - Q4 sales soared 225% YoY, with US momentum, cost cuts, and funding supporting 2025 targets.BIOVIC
Q4 23/24 - Sales doubled and partnerships expanded, but liquidity risk persists despite improved cash flow.BIOVIC
Q3 24/25
Next Biovica International earnings date
Next Biovica International earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)